Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia A

NCT04303559 is registered in ClinicalTrials.gov with Margaret Ragni as lead sponsor.

NCT NCT04303559
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04303559 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Multicenter, Randomized Phase III Inhibitor Prevention Trial, Comparing Eloctate vs. Emicizumab to Prevent Inhibitor Formation in Severe Hemophilia A
Lead sponsor
Margaret Ragni
Phase
Phase 3
Overall status
Terminated
Start date
October 11, 2021
Completion date
June 16, 2022
Enrollment
1 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a without inhibitor